194 related articles for article (PubMed ID: 33086721)
1. Heregulin Drives Endocrine Resistance by Altering IL-8 Expression in ER-Positive Breast Cancer.
Papadimitropoulou A; Vellon L; Atlas E; Steen TV; Cuyàs E; Verdura S; Espinoza I; Menendez JA; Lupu R
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33086721
[TBL] [Abstract][Full Text] [Related]
2. Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer.
Menendez JA; Mehmi I; Papadimitropoulou A; Vander Steen T; Cuyàs E; Verdura S; Espinoza I; Vellon L; Atlas E; Lupu R
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081219
[TBL] [Abstract][Full Text] [Related]
3. Heregulin controls ERα and HER2 signaling in mammospheres of ERα-positive breast cancer cells and interferes with the efficacy of molecular targeted therapy.
Fukui F; Hayashi SI; Yamaguchi Y
J Steroid Biochem Mol Biol; 2020 Jul; 201():105698. PubMed ID: 32404282
[TBL] [Abstract][Full Text] [Related]
4. Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage.
Menendez JA; Mehmi I; Lupu R
Int J Oncol; 2005 Mar; 26(3):649-59. PubMed ID: 15703820
[TBL] [Abstract][Full Text] [Related]
5. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
[TBL] [Abstract][Full Text] [Related]
6. Involvement of heregulin-beta2 in the acquisition of the hormone-independent phenotype of breast cancer cells.
Tang CK; Perez C; Grunt T; Waibel C; Cho C; Lupu R
Cancer Res; 1996 Jul; 56(14):3350-8. PubMed ID: 8764133
[TBL] [Abstract][Full Text] [Related]
7. Co-expression of HER2 and HER3 receptor tyrosine kinases enhances invasion of breast cells via stimulation of interleukin-8 autocrine secretion.
Aceto N; Duss S; MacDonald G; Meyer DS; Roloff TC; Hynes NE; Bentires-Alj M
Breast Cancer Res; 2012 Oct; 14(5):R131. PubMed ID: 23062209
[TBL] [Abstract][Full Text] [Related]
8. Nuclear moonlighting of the secreted growth factor heregulin drives endocrine-resistant breast cancer independently of HER2/HER3 signaling.
Yang L; Vander Steen T; Espinoza I; Cuyàs E; Verdura S; Menendez JA; Lupu R
Am J Cancer Res; 2022; 12(5):2173-2188. PubMed ID: 35693067
[TBL] [Abstract][Full Text] [Related]
9. Bidirectional interactions between the estrogen receptor and the cerbB-2 signaling pathways: heregulin inhibits estrogenic effects in breast cancer cells.
Grunt TW; Saceda M; Martin MB; Lupu R; Dittrich E; Krupitza G; Harant H; Huber H; Dittrich C
Int J Cancer; 1995 Nov; 63(4):560-7. PubMed ID: 7591267
[TBL] [Abstract][Full Text] [Related]
10. Her-2/neu-induced "cytokine signature" in breast cancer.
Vazquez-Martin A; Colomer R; Menendez JA
Adv Exp Med Biol; 2008; 617():311-9. PubMed ID: 18497054
[TBL] [Abstract][Full Text] [Related]
11. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
Kim J; Lee J; Kim C; Choi J; Kim A
Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression.
Menendez JA; Mehmi I; Lupu R
J Clin Oncol; 2006 Aug; 24(23):3735-46. PubMed ID: 16847284
[TBL] [Abstract][Full Text] [Related]
13. A functional comparison between the HER2(high)/HER3 and the HER2(low)/HER3 dimers on heregulin-β1-induced MMP-1 and MMP-9 expression in breast cancer cells.
Kim S; Han J; Shin I; Kil WH; Lee JE; Nam SJ
Exp Mol Med; 2012 Aug; 44(8):473-82. PubMed ID: 22627808
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional up-regulation of paxillin expression by heregulin in human breast cancer cells.
Vadlamudi R; Adam L; Tseng B; Costa L; Kumar R
Cancer Res; 1999 Jun; 59(12):2843-6. PubMed ID: 10383144
[TBL] [Abstract][Full Text] [Related]
15. Regulation of HRG-β1-induced proliferation, migration and invasion of MCF-7 cells by upregulation of GPR30 expression.
Ruan SQ; Wang SW; Wang ZH; Zhang SZ
Mol Med Rep; 2012 Jul; 6(1):131-8. PubMed ID: 22576740
[TBL] [Abstract][Full Text] [Related]
16. Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2.
Jhabvala-Romero F; Evans A; Guo S; Denton M; Clinton GM
Oncogene; 2003 Nov; 22(50):8178-86. PubMed ID: 14603258
[TBL] [Abstract][Full Text] [Related]
17. HER2/HER3 regulates extracellular acidification and cell migration through MTK1 (MEKK4).
Sollome JJ; Thavathiru E; Camenisch TD; Vaillancourt RR
Cell Signal; 2014 Jan; 26(1):70-82. PubMed ID: 24036211
[TBL] [Abstract][Full Text] [Related]
18. Heregulin-induced cell migration is promoted by aryl hydrocarbon receptor in HER2-overexpressing breast cancer cells.
Yamashita N; Saito N; Zhao S; Terai K; Hiruta N; Park Y; Bujo H; Nemoto K; Kanno Y
Exp Cell Res; 2018 May; 366(1):34-40. PubMed ID: 29501698
[TBL] [Abstract][Full Text] [Related]
19. Heregulin-β1-induced GPR30 upregulation promotes the migration and invasion potential of SkBr3 breast cancer cells via ErbB2/ErbB3-MAPK/ERK pathway.
Ruan SQ; Wang ZH; Wang SW; Fu ZX; Xu KL; Li DB; Zhang SZ
Biochem Biophys Res Commun; 2012 Apr; 420(2):385-90. PubMed ID: 22425775
[TBL] [Abstract][Full Text] [Related]
20. The HER2- and heregulin β1 (HRG)-inducible TNFR superfamily member Fn14 promotes HRG-driven breast cancer cell migration, invasion, and MMP9 expression.
Asrani K; Keri RA; Galisteo R; Brown SA; Morgan SJ; Ghosh A; Tran NL; Winkles JA
Mol Cancer Res; 2013 Apr; 11(4):393-404. PubMed ID: 23378579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
